Congress mandates free heart-disease screening for millions at risk
H.R. 10970 — Cardiovascular Disease Early Detection and Prevention Act of 2026 · Filed by Eugene Vindman (D-VA) · Introduced Nov 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans (private, Medicare, and Medicaid) to cover two cardiovascular blood tests—lipoprotein(a) and apolipoprotein B—without cost-sharing (copays, deductibles, coinsurance) for people with cardiovascular risk factors or disease history. The tests detect heart-disease risk better than standard cholesterol screening. Ordinary people with risk factors gain access to preventive testing at no out-of-pocket cost; insurers and government programs bear the cost of the tests.
Why we flagged it
The bill's core mechanism is a straightforward insurance mandate: require coverage of two specific cardiovascular tests without cost-sharing for at-risk populations. It is a public-health measure, not a tax provision, subsidy, or deregulation.
What the text implies
- Diagnostic labs and clinical testing companies will see increased demand for Lp(a) and ApoB testing, potentially expanding the market for these tests beyond current utilization rates.
- State Medicaid programs must comply with the benchmark-coverage requirement, potentially increasing state costs if they had not previously covered these tests; federal matching funds may offset some state burden.
- The bill's eligibility criteria (family history, prior MI/stroke, elevated LDL, diabetes, obesity, 'other recognized cardiovascular risk factors') are broad and may capture a significant portion of the adult population, expanding the covered population beyond initial estimates.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
People with cardiovascular risk factors gain access to preventive tests that detect disease risk earlier, without out-of-pocket cost, enabling earlier intervention and potentially preventing heart attacks and strokes. The cost is borne by insurers and public programs, not individuals.
Who stands to gain
- clinical laboratory companies
- diagnostic testing providers
- healthcare systems offering cardiovascular screening
Named in the bill
Centers for Medicare & Medicaid Services (CMS), Medicaid programs (state), private health insurers, group health plans, diagnostic laboratories
Where it stands
- Nov 9, 2026 — Introduced · Congress.gov: “Introduced in House”
- Nov 9, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,970 characters) on Nov 11, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-11-22.
“Congress mandates free heart-disease screening for millions at risk” QuorumCivic. https://share.quorumcivic.app/bill/119/hr10970 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.